Previous close | 40.77 |
Open | 39.35 |
Bid | 40.71 x 40000 |
Ask | 40.76 x 40000 |
Day's range | 40.00 - 40.80 |
52-week range | 29.20 - 40.80 |
Volume | |
Avg. volume | 2,612,314 |
Market cap | 260.946B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 20.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.35 (3.41%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.